Katherine E. Mues, PhD, MPH

Vice President
Aetion, Inc.

Poster(s):

• (102) Evaluation of postmenopausal hemorrhage following Moderna COVID-19 vaccines: results from surveillance data analysis and interim results from a US claims database cohort study
  Monday, August 26, 2024

  8:00 AM – 6:00 PM CEST

• (129) Safety of Moderna’s mRNA-1273.222 bivalent omicron-containing vaccine: interim results from a US claims database cohort study
  Monday, August 26, 2024

  8:00 AM – 6:00 PM CEST

• (150) Characterizing device and treatment of patients with deep dermal or full thickness thermal burns in the National Burn Registry between 2021-2023
  Tuesday, August 27, 2024

  8:00 AM – 6:00 PM CEST

• (341) Early use of Moderna’s mRNA-1273.815 monovalent vaccine: a descriptive analysis of a US Claims database
  Wednesday, August 28, 2024

  8:00 AM – 1:30 PM CEST